MX371143B - Forma farmaceutica para la liberacion prolongada de sustancias activas. - Google Patents

Forma farmaceutica para la liberacion prolongada de sustancias activas.

Info

Publication number
MX371143B
MX371143B MX2014015642A MX2014015642A MX371143B MX 371143 B MX371143 B MX 371143B MX 2014015642 A MX2014015642 A MX 2014015642A MX 2014015642 A MX2014015642 A MX 2014015642A MX 371143 B MX371143 B MX 371143B
Authority
MX
Mexico
Prior art keywords
active substances
pharmaceutical form
dosage form
active substance
prolonged release
Prior art date
Application number
MX2014015642A
Other languages
English (en)
Other versions
MX2014015642A (es
Inventor
Gernot Francas
Karl-Heinz Przyklenk
Original Assignee
Hennig Arzneimittel Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hennig Arzneimittel Gmbh & Co filed Critical Hennig Arzneimittel Gmbh & Co
Publication of MX2014015642A publication Critical patent/MX2014015642A/es
Publication of MX371143B publication Critical patent/MX371143B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una forma farmacéutica, que hace posible liberar uniformemente una sustancia activa durante un período de tiempo prolongado. La forma farmacéutica comprende un emulsionante con un motivo estructura de óxido de polialquileno. La forma farmacéutica es adecuada para liberar una segunda sustancia activa junto con la primera sustancia activa. Se obtiene una liberación uniforme aun cuando dos sustancias activas tienen propiedades completamente diferentes en términos de solubilidad. También se describe un método para la producción de la forma farmacéutica y su uso.
MX2014015642A 2012-06-25 2013-06-24 Forma farmaceutica para la liberacion prolongada de sustancias activas. MX371143B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012105512.2A DE102012105512A1 (de) 2012-06-25 2012-06-25 Arzneiform zur verlängerten Freisetzung von Wirkstoffen
PCT/EP2013/063163 WO2014001268A1 (de) 2012-06-25 2013-06-24 Arzneiform zur verlängerten freisetzung von wirkstoffen

Publications (2)

Publication Number Publication Date
MX2014015642A MX2014015642A (es) 2015-08-05
MX371143B true MX371143B (es) 2020-01-20

Family

ID=48670585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015642A MX371143B (es) 2012-06-25 2013-06-24 Forma farmaceutica para la liberacion prolongada de sustancias activas.

Country Status (22)

Country Link
EP (1) EP2863891B1 (es)
KR (1) KR102160837B1 (es)
AU (1) AU2013283474B2 (es)
BR (1) BR112014032583B1 (es)
CA (1) CA2876294C (es)
CO (1) CO7240370A2 (es)
DE (1) DE102012105512A1 (es)
EA (2) EA028064B1 (es)
ES (1) ES2817248T3 (es)
HR (1) HRP20201534T1 (es)
HU (1) HUE050945T2 (es)
IL (1) IL236465B (es)
IN (1) IN2014MN02511A (es)
LT (1) LT2863891T (es)
MX (1) MX371143B (es)
PH (1) PH12014502834B1 (es)
PL (1) PL2863891T3 (es)
PT (1) PT2863891T (es)
RS (1) RS60872B1 (es)
SI (1) SI2863891T1 (es)
UA (1) UA116776C2 (es)
WO (1) WO2014001268A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP2959887B1 (de) 2014-06-26 2018-11-14 Hennig Arzneimittel GmbH&Co. Kg Arzneimittel zur Behandlung von Schwindel verschiedener Genese
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
KR101625344B1 (ko) * 2015-12-21 2016-06-08 주식회사 유영제약 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
ATE232087T1 (de) * 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
EP1942888A2 (en) 2005-11-02 2008-07-16 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
CN101049309A (zh) * 2006-04-03 2007-10-10 陈茜 桂利嗪滴丸及其制备方法
HRP20191104T1 (hr) * 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
MX2010006005A (es) 2007-12-12 2010-06-15 Basf Se Sales de ingredientes activos con contraiones polimericos.
RU2527328C2 (ru) * 2009-06-11 2014-08-27 ФотоКьюэр АСА Твердые композиции, содержащие 5-аминолевулиновую кислоту
WO2011024029A1 (en) 2009-08-24 2011-03-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Fast disintegrating dosage forms of cinnarizine and dimenhydrinate combination
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
DE102011051304A1 (de) 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Wirkstoffmatrix
DE102011053068A1 (de) * 2011-08-29 2013-02-28 Hennig Arzneimittel Gmbh & Co. Kg Darreichungsform mit stabilisierten Wirkstoffpartikeln

Also Published As

Publication number Publication date
IL236465B (en) 2020-06-30
PT2863891T (pt) 2020-09-25
AU2013283474B2 (en) 2017-12-14
PH12014502834B1 (en) 2019-12-04
IN2014MN02511A (es) 2015-07-17
EP2863891B1 (de) 2020-08-26
EA035815B1 (ru) 2020-08-14
KR102160837B1 (ko) 2020-09-29
CA2876294A1 (en) 2014-01-03
RS60872B1 (sr) 2020-11-30
SI2863891T1 (sl) 2020-11-30
BR112014032583A8 (pt) 2021-06-22
CA2876294C (en) 2020-09-08
PL2863891T3 (pl) 2021-01-25
EA201500043A1 (ru) 2015-09-30
PH12014502834A1 (en) 2015-02-02
DE102012105512A1 (de) 2014-04-24
EA201792143A1 (ru) 2018-05-31
HRP20201534T1 (hr) 2021-02-19
BR112014032583B1 (pt) 2022-05-17
WO2014001268A1 (de) 2014-01-03
IL236465A0 (en) 2015-02-26
AU2013283474A1 (en) 2015-01-29
EA028064B1 (ru) 2017-10-31
ES2817248T3 (es) 2021-04-06
EP2863891A1 (de) 2015-04-29
HUE050945T2 (hu) 2021-01-28
MX2014015642A (es) 2015-08-05
CO7240370A2 (es) 2015-04-17
KR20150041612A (ko) 2015-04-16
LT2863891T (lt) 2020-12-10
BR112014032583A2 (pt) 2017-06-27
UA116776C2 (uk) 2018-05-10

Similar Documents

Publication Publication Date Title
CO7240370A2 (es) Forma farmaceútica para la liberación prolongada de sustancias activas
CY1121712T1 (el) Γελη λυματος αιμοπεταλιων
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
CL2014000370A1 (es) Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
MX374129B (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos.
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
CL2013000718A1 (es) Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades.
IN2014MN02214A (es)
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2015000254A1 (es) Vesículas que comprenden factor de crecimiento epidermico (egf); proceso de preparación; composición farmacéutica que las comprende; y uso para tratar heridas complejas .
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
BR112013022556A8 (pt) composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
BR112014020992A2 (pt) Composto,uso de composto na fabricação de um medicamento e composição farmacêutica
EP2552426A4 (en) DEVICE FOR DELIVERY OF INTRAVAGINAL DRUGS
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
BR112013019924A2 (pt) composições para cuidado oral
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
UA119441C2 (uk) Посилювачі водорозчинності на основі глікогену
CL2018000566A1 (es) Formulaciones de pirofosfato férrico sólido soluble, kits, y métodos de uso de las mismas
CL2015001308A1 (es) Pastilla medicinal para chupar a base de ibuprofeno sodico dihidratado; metodo de preparación y el uso en el tratamiento de los trastornos orofaringeos.
CL2008003711A1 (es) Proceso para preparar una forma de dosificación farmaceutica que comprende florfenicol o un análogo de este; y para recuperar florfenicol o un análogo de una composición farmacéutica.

Legal Events

Date Code Title Description
FG Grant or registration